Skip to content
Evigrade
MajorAntiretroviral, HIV protease inhibitor×Glucocorticoids

Updated · Methodology

Mechanism

CYP3A4, a liver enzyme, metabolises atazanavir, and dexamethasone is a moderate inducer of this enzyme (dexamethasone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), so atazanavir levels may fall (atazanavir label, US Food and Drug Administration, FDA). Atazanavir itself inhibits CYP3A4, and ritonavir, part of the recommended atazanavir regimen, inhibits it more strongly than atazanavir (atazanavir SmPC, European Medicines Agency, EMA). CYP3A4 also metabolises dexamethasone, so human immunodeficiency virus (HIV) protease inhibitors may raise its plasma levels and reduce its clearance (AEMPS). When boosted with cobicistat, atazanavir is more sensitive to CYP3A induction than with ritonavir (atazanavir/cobicistat SmPC, EMA).

Symptoms

Lower atazanavir levels may lead to loss of its effect against the human immunodeficiency virus (HIV) and to resistance to atazanavir or ritonavir (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Higher corticosteroid levels, particularly with long-term use, may increase the risk of systemic effects, including Cushing's syndrome and adrenal suppression (EMA). Typical signs of Cushing's syndrome with dexamethasone are a moon face, facial plethora and truncal obesity (dexamethasone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Too rapid a dose reduction after long treatment can lead to acute adrenal insufficiency, hypotension and death (AEMPS).

Management

Consider other corticosteroids instead of dexamethasone, because dexamethasone may cause atazanavir to lose its antiviral effect (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). Atazanavir is not recommended with CYP3A4 inducers. Atazanavir with ritonavir is not recommended with glucocorticoids metabolised by CYP3A4 unless the potential benefit outweighs the risk of systemic corticosteroid effects (EMA). Dexamethasone belongs to both groups (dexamethasone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The atazanavir contraindication covers strong CYP3A4 inducers (EMA), and the dexamethasone SmPC describes dexamethasone as a moderate inducer (AEMPS). The dexamethasone SmPCs advise avoiding combinations with CYP3A inhibitors unless the benefit outweighs the increased risk of systemic corticosteroid adverse reactions. If the combination is prescribed, patients are monitored for these reactions, and the dexamethasone dose can be reduced if necessary (AEMPS). The same recommendations apply if ritonavir is removed from the regimen (EMA). For atazanavir with cobicistat, the US label also advises considering other corticosteroids (atazanavir/cobicistat label, FDA). When dexamethasone is withdrawn, a slow dose reduction can minimise the risk of acute adrenal insufficiency (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Dexamethasone